Skip to main content
. 2024 Jul 23;5:81. doi: 10.1186/s43058-024-00609-5

Table 4.

Adherence for content, dose, and duration by facility level and overall (n = 254 FCM administrations)

Content Primary (five facilities) (n = 75) (%) Secondary (four facilities) (n = 160) (%) Tertiary (two facilities)
(n = 19) (%)
All facilities (n = 254) (%)
1. Ensure the availability of the following resuscitation medications and materials at the point of administration
i. Adrenaline 61 (81.3) 144 (90.0) 17(89.4) 222(87.4)
ii. IV Chlorpheniramine 57 (76.0) 144 (90.0) 16 (84.2) 217 (85.4)
iii. IV Ranitidine 61 (81.3) 144 (90.0) 17 (89.5) 222 (87.4)
iv. Oral Ranitidine 55 (73.3) 141 (88.1) 16 (84.2) 212 (83.5)
v. IV hydrocortisone 61 (81.3) 154 (96.2) 17 (89.5) 232 (91.3)
vi. 500mls/1L bottle normal saline 61 (81.3) 156 (97.5) 17 (89.5) 234 (92.1)
vii. Intravenous fluid giving set 63 (84.0) 160(100.0) 18 (94.7) 241 (94.9)
viii. Oxygen mask 40 (53.3) 131 (81.9) 16 (84.2) 187 (73.6)
ix. Oxygen cylinder 38 (50.7) 158 (98.8) 17 (89.5) 213 (83.9)
Total median score for component 1 (IQR) 88.9 (66.7–100.0) 100.0 (100.0,100.0) 100.0 (100.0,100.0) 100.0 (88.9–100.0)
2. Ensure availability of FCM 75 (100.0) 160(100.0) 19(100.0) 254 (100.0)
3. Patient counselling 62 (82.7) 160(100.0) 19(100.0) 241 (94.9)
4. Confirm patient’s randomization group is FCM 75 (100.0) 160(100.0) 19(100.0) 254 (100.0)
5. Obtain verbal consent for FCM administration from participants 65 (86.7) 159 (99.4) 19 (100.0) 243 (95.6)
6. Perform baseline vital signs 65 (86.7) 159 (99.4) 19 (100.0) 243 (95.6)
7. Calculation of individual dose at 20 mg/Kg body weight up to a maximum dose of 1000 mg 75 (100.0) 156 (97.5) 19 (100.0) 250 (98.4)
8. Set up the administration at a low flow rate 70 (93.3) 158 (98.8) 19 (100.0) 247 (97.3)
9. Observe the patient closely and monitor vital signs for the first 2 min 59 (78.7) 159 (99.4) 19 (100.0) 237(93.3)
10. Post-administration vital signs check 54 (72.0) 160(100.0) 19 (100.0) 233 (91.7)
Total median score for content (IQR) 97.8 (81.1–100.0) 100 (100.0, 100.0) 100 (100.0, 100.0) 100.0 (97.8–100.0)
Dose
Withdraw the equivalent volume of the calculated dose 75 (100.0) 159(99.4) 19 (100.0) 253 (99.6)
Duration
Patient is observed for adverse effects for at least 30 min following administration 69 (92.0) 155 (96.9) 18 (94.7) 242 (95.3)

IQR Interquartile range